Actinogen Medical Limited ACW

Actinogen Medical CFO Will Souter talked with Proactive about the completion of the final patient visit in the company’s pivotal XanaMIA Phase 2b/3 Alzheimer’s disease trial and what investors can expect ahead of top-line results in November. Souter described the final patient visit as “a major milestone in any clinical trial”, noting that XanaMIA has progressed through an interim analysis and three meetings of its independent data monitoring committee. He also highlighted the significant time and effort involved in running the study, with patients undergoing treatment for 36 months. Looking a

This phase 2b/3, double-blind trial of oral Xanamem in 247 participants with mild to moderate Alzheimer’s disease and elevated pTau181 evaluates the potential benefit of targeting excess cortisol in the brain over a 36-week treatment periodSYDNEY, Australia, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Actinogen Medical Limited (ASX: ACW) today announces that, following the final participant visit on 22 September in the USA, topline results for the XanaMIA phase 2b/3 Alzheimer’s disease (AD) clinical tria